Therapeutic Response

MSI-H status confers therapeutic sensitivity to Carboplatin in combination with Dostarlimab and Paclitaxel in patients with Endometrial Carcinoma.

Statements

Source and description

Jemperli (dostarlimab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to dostarlimab in combination with carboplatin and paclitaxel, followed by dostarlimab as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microstallite instability-high (MSI-H).